AIM:To investigate the association of hepatitis B virus (HBV)genotype and HBeAg seroconversion after nucleotideanalogue treatment.METHODS:Chronic hepatitis B patients receiving lamivudinefollowed up for at least 6 months post-treatment werestudied.Consecutive treatment-naive patients who wereprospectively followed up in the clinic for at least 18 monthswere studied as controls.HBeAg seroconversion was definedas loss of HBeAg,appearance of anti-HBe and normalizationof alanine aminotransferase for at least 6 months.RESULTS:Thirty-five patients on lamivudine and 96 controlpatients followed up for 39 (18-49) months were studied.Lamivudine was given for 12 (10-18) months,and patientswere followed up for 15 (6-34) months after drug cessation.Genotype B and C HBV were found in 43 and 88 patientsand HBeAg seroconversion occurred in 12 (28 %) and 16(18 %) patients,respectively (P=0.30).There was nodifference in HBeAg seroconversion between patientsinfected by genotype B and C HBV in the control (35 % vs21%,P=0.25) and lamivudine-treated (14 % vs 10 %,P= 1.00) groups.coclusion:HBeAg seroeonversion after treatment bylamivudine was not influeneed by the HBV genotype AIM: To investigate the association of hepatitis B virus (HBV) genotype and HBeAg seroconversion after nucleotideanalogue treatment. METHODS: Chronic hepatitis B patients receiving lamivudine follow up for at least 6 months post-treatment were staged. Consecutive treatment-naive patients who wereprospectively followed up in the clinic for at least 18 monthswere studied as controls. HBeAg seroconversion was defined as loss of HBeAg, appearance of anti-HBe and normalization of alanine aminotransferase for at least 6 months .RESULTS: Thirty-five patients on lamivudine and 96 controlpatients followed up for 39 ( 18-49) months were studied. Lamivudine was given for 12 (10-18) months, and patientswere followed up for 15 (6-34) months after drug cessation. Genotype B and C HBV were found in 43 and 88 patients and HBeAg seroconversion occurred in 12 (28%) and 16 (18%) patients, respectively (P = 0.30). There was nodifference in HBeAg seroconversion between patients infected by genotype B and C HBV in the control (35% vs 21%, P = 0.25) and lamivudine-treated (14% vs 10%, P = 1.00) groups.coclusion: HBeAg seroeonversion after treatment bylamivudine was not influened by the HBV genotype